Invivyd Appoints Fred Driscoll as Interim Chief Financial Officer and Announces Resource Reallocation to Maximize Integrated Discovery Platform
October 13, 2022 16:01 ET
|
Invivyd
WALTHAM, Mass., Oct. 13, 2022 (GLOBE NEWSWIRE) -- Invivyd, (Nasdaq: IVVD) a clinical-stage biopharmaceutical company on a mission to protect humanity from serious viral respiratory diseases, today...
Invivyd to Present Multiple Posters Highlighting Clinical Data from Adintrevimab During ID Week 2022
October 12, 2022 16:01 ET
|
Invivyd
WALTHAM, Mass., Oct. 12, 2022 (GLOBE NEWSWIRE) -- Invivyd, (Nasdaq: IVVD), formerly Adagio Therapeutics (Nasdaq: ADGI), a clinical-stage biopharmaceutical company on a mission to protect humanity...
Adagio Therapeutics Announces Corporate Name Change to Invivyd
September 12, 2022 07:00 ET
|
Adagio Therapeutics, Inc.
New name reflects Company focus on leveraging its integrated discovery platform to generate anti-viral antibodies that transcend the limits of naturally occurring immunityThe Invivyd corporate mission...
Adagio Therapeutics to Participate in Upcoming Investor Conferences
September 06, 2022 16:01 ET
|
Adagio Therapeutics, Inc.
WALTHAM, Mass., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Adagio Therapeutics, Inc. (Nasdaq: ADGI), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of...
Adagio Therapeutics Reports Second Quarter 2022 Financial Results and Business Highlights
August 15, 2022 06:30 ET
|
Adagio Therapeutics, Inc.
$475 Million in Cash and Cash Equivalents to Support Operating Runway into Second Quarter of 2024 Integrated Discovery Platform Identifies Multiple New Candidates for COVID-19 Prevention and...
Adagio Announces David Hering Named Permanent Chief Executive Officer and Director
July 05, 2022 07:26 ET
|
Adagio Therapeutics, Inc.
WALTHAM, Mass., July 05, 2022 (GLOBE NEWSWIRE) -- Adagio Therapeutics, Inc. (Nasdaq: ADGI), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of...
Adagio Announces Results of Annual Meeting of Stockholders and Evolution of the Board of Directors
July 01, 2022 06:30 ET
|
Adagio Therapeutics, Inc.
WALTHAM, Mass., July 01, 2022 (GLOBE NEWSWIRE) -- Adagio Therapeutics, Inc. (Nasdaq: ADGI), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of...
Adagio Therapeutics Reports First Quarter 2022 Financial Results
May 13, 2022 06:30 ET
|
Adagio Therapeutics, Inc.
$532.2 Million in Total Cash at Quarter End; Strong Balance Sheet Expected to Support Operations into Second Half of 2024 Additional Data from Adintrevimab Phase 2/3 STAMP Treatment Trial to be...
Adagio Therapeutics Provides Update on Timing of Adintrevimab EUA Request
April 14, 2022 07:45 ET
|
Adagio Therapeutics, Inc.
WALTHAM, Mass., April 14, 2022 (GLOBE NEWSWIRE) -- Adagio Therapeutics, Inc. (Nasdaq: ADGI), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of...
Adagio Therapeutics annonce que l'ADG20 (adintrevimab) est le premier anticorps monoclonal à répondre aux critères d'évaluation primaires ayant une importance statistique dans l'ensemble de la prophylaxie pré et post-exposition et du traitement pour la COVID-19, et prévoit de demander une autorisation d'utilisation d'urgence aux États-Unis
March 31, 2022 17:01 ET
|
Adagio Therapeutics, Inc.
Le risque de COVID-19 symptomatique a été réduit de 71 % par rapport au placebo dans la prophylaxie pré-exposition et de 75 % par rapport au placebo dans la prophylaxie post-exposition Le risque...